F8 and hemophilia A: This study aimed to assess real-world outcomes in people with severe haemophilia A using marketed FVIII products, with the goal of increasing knowledge and understanding of the disease burden, treatment gaps, and unmet needs, in consideration of a rapidly changing haemophilia treatment landscape.